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INTRODUCTION
This issue of the 1\1/CV Q11ar1er/_1· is devoted
to the 48th Annual McGuire Lecture Series held
on February 12-13. 1977. The lectures. presented
this year by the Depart111ent of Continuing Educa
tion. were designed to focus upon the ever-increasing
amount of new information being generated in the
lie Id of i 111munology.
The progra111 title. "J111munology Update.'· is
indicative of our attempt to provide a co111pre
hensive view of the latest research lindings and
developments and their implications for the clinical
setting. Topics addressed included: (a) an overvie\\'
of basic immunology: (b) a discussion of the clini
cal manifestations and management of immuno
logical disorders: (c) presentations on ho\\' to do
ollice work-ups of immunological problems: and
(d) discussions on the use of immunological diag
nostic techniques.
We wen; fortunate to have as our McGuire
Lecturer. Richard Hong. M.D .. Professor of Pedi
atrics. University of Wisconsin School of Medicine.
Madison. Wisconsin. Dr. Hong is recogniled inter
nationally ;1s one of the outstanding authorities on
immunology. Nine other highly capable physicians
comprised an outstanding faculty. We are in their
debt for providing a series of lectures that proved
attractive lo physicians. as was reflected by the
large attendance. and one that \\'as stimulating and
infor111;1tive.
D/\VJD B. WALTHALL. JR.. M.D.
Assis1w11 /)<'all for C11111i1111i11g Meli1ca/ Lt!11c111io11

The Emerging Clinical Usefulness of
Complement Measurements*
SHAUN RUDDY. M.D.

Professor of Medicine and Microbiology, and Chairman. Division of Immunology and Connective Tissue Diseases.
f
Medical College of Virginia, Health Sciences Division o Virginia Commonwealth University, Richmond, Virginia

Not many years ago the main purpose of "com
plement" seemed to be to drill holes in sheep eryth
rocytes. In the classic experiment which was part of
every medical student's microbiology laboratory ex
perience, a magic stuff called complement, somewhat
mysteriously obtained from guinea pigs. was either
"fixed" or not "fixed" and the sheep cells either not
lysed or lysed accordingly.'That was about all there
was to know about complement, and all one needed
to know.
Today the term "complement" embodies a
group of plasma proteins which react in a complex
sequence to mediate a variety of inflammatory ef
fects, including changes in vascular permeability, the
attraction of polymorphonuclear or mononuclear
leukocytes, the enhancement of phagocytosis. and
damage to cell membranes and osmotic lysis such as
the sheep erythrocyte suffered in the complement fix
ation test. These complement proteins rival the in
trinsic coagulation scheme in complexity and re
semble it in mechanism, that is. the complement
proteins normally circulate in the plasma in an in
active or precursor form, and when appropriately
stimulated, usually during an immunologic reaction,
become transformed into active enzymes, or pro
teases. These proteases act upon their natural sub
strates (other members of the complement system) in
an orderly and predetermined sequence of limited
• This work was supported by NIH grants Al 13049 and AM
18976. and an Arthritis Clinical Research Center Grant from the
Arthritis Foundation. New York. This is publication no. 111 from
the Charles W. Thomas Arthritis Fund. Medical College of Vir
ginia.
Correspondence and reprint requests to Dr. Shaun Ruddy.
Box 263. Medical College of Virginia. Richmond. Virginia 23298.
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proteolytic reactions which are often compared to a
"cascade" or "waterfall." Cleavage of one com
ponent leads to the activation of the next component,
and so forth. Natural inhibitors or inactivators also
present in plasma serve to modulate or damp this
cascade system and prevent its getting out of control.
In fact, congenital deficiency of one of these inhib
itors, the Cl Inhibitor, leads to uncontrolled activa
tion of the system and recurrent swelling of the sub
epithelial tissues of the skin, respiratory and
gastrointestinal tracts.2

Biochemical Pathways.•-•

Two pathways for activation. the classic and
alternative (properdin ), initiate the terminal attack
sequence which elaborates most of the biologic activi
ties associated with complement. The classic pathway
is activated by immune complexes containing IgG or
lgM immunoglobulins and their associated antigens.
The properdin pathway is activated by certain kinds
of repeating polysaccharides such as pneumococcal
polysaccharide, or the bacterial lipopolysaccharide of
gram-negative endotoxin: immune complexes con
taining lgA may also activate the properdin system.
Regardless of which pathway is activated, both
result in the cleavage of C3 and CS. Peptides released
from these components, C3a and CSa, are anaphy
latoxins capable of releasing histamine from mast
cells and thereby influencing local vascular per
meability. CSa also releases lysosomal enzymes and
presumably other granular contents from poly
morphonuclear leukocytes. Both C3a and CSa have
chemotactic activity as well, the latter being more
active in most systems: the trimolecular complex
formed from CS, C6, and C7 is also chemotactic.
Immune complexes to which complement, especially
45
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C3b, has become bound adhere to poly
morphonuclear neutrophils, mononuclear cells and
B-lymphocytes. Although the functional significance
of these binding phenomena is not yet entirely clear,
enhanced phagocytosis by mononuclear or poly
morphonuclear cells is certainly one consequence.
Formation of a multimolecular complex involving
CS, C6, C7, C8, and C9 leads to the membrane dam
age and osmotic lysis which have become the hall
marks of complement activation.
Metabolism of Complement Proteins.

One result of the proteolysis of the complement
proteins during their activation is that they sub
sequently become recognizable as "altered" or "for
eign" by the body and are rapidly cleared from the
circulation. Although some compensatory increases
in synthesis may occur, the result is usually a fall in
plasma level. Thus, an ongoing immunologic event
(or disease) which is activating the complement sys
tem in vivo may be manifested as a fall in the serum
or plasma level of one or more of the complement
proteins. In reverse fashion, as the complement-acti
vating stimulus or disease abates, this may be paral
leled by a return towards normal in the complement
levels.
Determinations of Complement in the Clinical Pa
thology Laboratory.

In principle, there are two ways of measuring
complement: (I) by its activity in the reaction it ca
talyzes, for example, the total hemolytic complement
or CHSO, which measures the result of the interaction
of all nine of the classic complement components or
(2) by its antigenicity, as a protein in an immunoas
say which takes advantage of the complement pro
tein's capacity to react with monospecific antibody
directed against it. In practice, although total he
molytic complement or CHSO determinations are
available in some institutions, immunoassays (usually
radial immunodiffusion) are most frequently avail
able. Materials for these are offered in the form of
kits for use in the clinical pathology laboratory by a
number of commercial suppliers.
A few comments are in order about the radial
immunodiffusion determinations for complement
components available in most hospitals.
I) Radial immunodiffusion, by its very nature,
is not nearly as precise a determination as
most physicians have come to expect from
clinical laboratories. Under the best condi
tions, the coefficient of variation of the tesl. is
likely to be 8% or greater, more than twice

that of commonly available clinical chemistry
or hematologic procedures. Thus in inter
preting the results of the test, the physician
must take into account this reduced preci
sion, for example, a "fall" in C3 level from
I45 to I 30 mg/ I 00 ml from one day to the
next may reflect only laboratory variation.
2) There are no widely available standards, so
that considerable variation in absolute values
obtained by kits from different suppliers or
even in lots of kits from the same supplier
may be observed. This should not be a prob
lem if results are referred to a normal range
collected at the institution in which the test is
being performed, and if appropriate internal
standards, maintained at the institution, are
assayed in parallel with the test samples. If
the "normal ranges" provided with the kits
are accepted as verbatim, and if independent
checks of the performance of the kits are
neglected, then unreliable data may result.
3) As for other plasma proteins, the range of
normal for complement proteins is quite
broad, usually in the vicinity of± 50% of the
mean value for the population. Thus changes
in levels in a single patient over a period of
time may often be more helpful and easier to
interpret than are comparisons with some ab
solute range of normal. For example. a pa
tient with suspect systemic lupus erythema
tosus whose C4 level fell from 70 mg/ I 00 ml
to 30 mg/JOO ml within two weeks might be
cause for alarm, even though the latter value
was still "within the range of normal."
4) The most widely available test for a com
plement component (C3) is not necessarily
the most desirable. Its availability is directly
related to the fact that C3 is by far the most
plentiful of the complement components. the
easiest to purify. and therefore the easiest to
make antibody against for use in a radio
immunoassay. Measurements of C3 were
therefore widely available from commercial
sources several years in advance of measure
ments of other components. Most workers
would agree today, however, that measure
ments of C4 are likely to be more sensitive to
minor episodes of in vivo complement activa
tion. and that a good "routine" complement
screen would include measurements of C4,
C3, and possibly CHSO.
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5) The immunoassays do not distinguish be
tween native protein and that which has par
ticipated in complement activation and lost
its activity but not its immunogenicity. They
are reliable, therefore, only in instances in
which substantial amounts of cleaved, in
active protein would not be expected. Altered
complement proteins are cleared within a few
hours from the plasma space, and the finding
of altered inactive protein in plasma requires
special techniques to detect the small
amounts which are present. In contrast, how
ever, altered inactive protein may persist for
much longer times in joint spaces or pleural
spaces, so that radial immunodiffusion deter
minations of C3 or C4 in synovial or pleural
fluid are of very little value. Recent studies
have shown that measurements of C4 in cere
brospinal fluid are similarly of little diagnos
tic value with respect to the presence or ab
sence of central nervous system involvement
in systemic lupus erythematosus.
Clinical Significance.

Given the knowledge that the complement sys
tem may be activated in vivo by immunologic dis
eases, and that simple and reliable methods for mea
suring complement levels are now widely available,
how can the practitioner best use this information?
What are the diseases in which complement measure
ments are likely to be of help, either in diagnosis or in
following the course of the patient? The answer is
simple: any disease in which the physician suspects
that circulating immune complexes may be playing a
pathogenetic role. A few of them are listed in the Table.
Systemic lupus erythematosus is the disease
which is perhaps most commonly associated with
hypocomplementemia, but it is well to bear in mind
that other diseases in which circulating antigen-an-

TABLE
Diseases in which Complement Determinations May Provide Useful
Diagnostic or Therapeutic Information
Systemic lupus erythematosus
Rheumatoid arthritis (with systemic vasculitis)
Hypersensitivity angiitis
Angioedema
Glomerulonephritis
Subacute bacterial endocarditis
Hepatitis
Essential mixed cryoglobulinemia
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tibody complexes may be found may also give rise to
hypocomplementemia. Among these would be in
cluded any cause of "chronic antigenemia," for ex
ample, subacute bacterial endocarditis, hepatitis B
surface antigenemia, infected atrioventricular shunts,
recurrent gram-negative sepsis, recurrent viremias
such as dengue hemorrhagic fever, or recurrent para
sitemia, such as falciparum malaria. Other diseases of
unknown etiology may be associated with hypo
complementemia, such as essential mixed cryoglo
bulinemia, or certain kinds of nephritis (which in
contrast to all the diseases mentioned above which
are likely to have low C4, and sometimes low C3,
usually have only low C3, suggesting direct alterna
tive pathway activation). The symptom of "angioed
ema" is infrequently associated with hypocomple
mentemia, but a screening test should be done for C4,
which is low in almost all cases of hereditary angioed
ema. especially since very effective treatment for this
disease is now available.
In most instances in which hypocomplemen
temia is found in association with the disease, im
provements in complement levels are often early and
reliable indices that the disease is ameliorating either
spontaneously or as a result of therapy.
Thus, by applying his understanding of "com
plement fixation," obtained in the classical micro
biology laboratory experiment, to human diseases in
which "complement fixation" appears to be occur
ring in vivo, today's physician has achieved a useful
diagnostic tool and therapeutic index in the measure
ment of complement components in disease.
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Immunology and Diseases of Connective
Tissue*
ROBERT IRBY, M.D.
Professor of Medicine, Division of Immunology and Connective Tissue Diseases. Medical College of Virginia,
Health Sciences Division of Virginia Co111111onwealth University, Richmond. Virginia

Since immune responses play a major role in the
development or connective tissue diseases, it is not
surprising that a number of laboratory studies reflect
these responses. Prior to the 1940s when rheumatoid
and LE factors became widely known, one relied
mainly on erythrocyte sedimentation rate and serum
electrophoresis to identify protein abnormality. Ele
vated sedimentation rate depends on rouleaux forma
tion, and rouleaux formation is dependent upon large
asymmetric molecules of fibrinogen and gamma
globulin in plasma. The demonstration of gamma
globulin has become the cornerstone of the immuno
logist's edifice. It is amazing to see how the sub
specialty or immunology has mushroomed to involve
the many facets of disease processes such as con
nective tissue diseases, skin diseases, gastrointestinal
diseases, renal diseases, and cancer. More recently,
immune deficiency diseases have included the pe
diatrician in the ever-enlarging field of immunology
as has the modern-day discovery of human leukocyte
antigen (H L-A) testing and tissue typing included the
geneticist.
In this paper, I will discuss four connective tissue
diseases-rheumatoid arthritis, ankylosing spondy
litis, systemic lupus erythematosus, and mixed con
nective tissue disease syndrome-and the role immu
nological processes play in their pathogenesis. I will
also comment upon certain laboratory tests that use
immunological methods in making a diagnosis.
• This is publication No. 110 f"rorn the Charles W. Thomas
Arthritis Fund. Medical College or Virginia.
Correspondence and reprint requests to Dr. Robert Irby, Di

vision of Immunology and Connective Tissue Diseases, Box 788.
Medical College of Virginia. Richmond, Virginia 23298.
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I. Rheumatoid Arthritis.
It is believed that an immune process plays a role
in the perpetuation of rheumatoid arthritis and there
are at least five items which may provide evidence for
this hypothesis.
I. Lymphoid cell infiltration of the synovial
membrane with follicle formation. Note sim
ilarity to architecture of lymph node (Figs IA
and IB).
2. Local synthesis of IgG and rheumatoid factor
by plasma cells in the synovium as demon
strated by Smiley et al.'
3. Decreased synovial fluid complement in some
cases. and in other cases decreased serum
complement as demonstrated by Ruddy and
Schur.'· 3
4. Presence of lgG and IgM and complement
components in the synovial lining cells and in
remote sites of tissue damage indicating that
some immunological process is taking place
also at distant sites.'
5. Presence of rheumatoid factor components
and complement in leukocytes of synovial
fluid cells.'
The current concept is that IgG is produced in
rheumatoid synovial membrane by an unknown stim
ulus: this in turn stimulates production of lgM by
plasma cells of the synovium and lymph nodes. Why
IgG. which is a product of the human system, should
serve as an antigen for IgM antibody production. is
unknown: however. immune events may depend
upon circulating complexes which may or may not be
important in pathogenesis. There are some who feel
that rheumatoid factor plays a protective role similar
to the antistreptolysin titer in streptococcal infection,
MCV QUARTERLY 13(2):48-56. 1977
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test is the most specific for the presence of rheuma
toid factor. Sometimes there are false-positive latex
tests in older patients and in patients with large
amounts of gamma globulin present. The SSC may
be positive in low titers and in other connective tissue
diseases. In general, all three tests employ the same
principle. The particle, whether it be latex, human red
cells, or sheep cells, is coated with lgG from one
source or another, which will agglutinate in the pres
ence of rheumatoid factor. If the sheep cell test is
positive in a significant titer, the chances are over 90%
that the patient has rheumatoid arthritis. It should be
remembered that a large number of patients do not
show rheumatoid factor, and these patients are classi
fied as seronegative rheumatoid arthritis patients (Fig
4 and Fig 5).
We can identify rheumatoid factor in serum,
demonstrate that it is produced by plasma cells in the
synovium, and can state that in certain cases of rheu
matoid arthritis it plays a pathogenetic role.

Fig IA-Microscopic view (medium power) of synovial mem
brane showing "nesting" of lymphocytes in perivascular area of
synovium.

while others feel that in certain systems it plays a part
in the inflammatory mechanism. The basic pathology
in these diseases seems to be vasculitis; hence the term
collagen-vascular disease arose, which is a misnomer,
since collagen is not the only connective tissue in
volved. In rheumatoid arthritis with high rheumatoid
factor titers and many subcutaneous nodules, one is
more likely to see those with severe disease: pe
ripheral neuritis, vasculitis, and leg and fingertip ulce
rations. In these patients one may find evidence of
antigen-antibody complement complex deposition in
the vessels leading to the ulcers and in the perineural
vessels of the peripheral nerves (Figs 2A, 28 and Figs
3A, 38).
There are a number of immunological tests
available to make a diagnosis of rheumatoid arthritis.
The three currently in use at the Medical College of
Virginia are the slide latex test, sensitized human cell
test (SHC), and the sensitized sheep cell test (SSC).
The latex test is the most sensitive and the sheep cell

Fig JB-View (lower power) showing follicle formation within
the synovium. Note similarity lo microscopic picture of lymph
node. This is thought to be the site of rheumatoid factor syn
thesis.
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Fig 2A-lndolent leg ulcer in a 64-year-old male with rheuma
toid arthritis which ultimately required below-the-knee amputa

Fig )A-Digital vasculitis in a patient with rheumatoid ar
thritis with gangrenous changes.

tion.

II. Ankylosing Spondylitis.

We generally categorize this as a separate disease
entity from rheumatoid arthritis, although it has
many similarities to that disease. There are, however,
five specific differences:
I. Sex and age of onset-more common in
young males.
2. Spine and girdle joints involved as opposed to
peripheral joints, although peripheral joints
may be involved in ankylosing spondylitis.
3. Pathology is that of ankylosis, rather than
bone destruction as seen in peripheral arthri
tis.
4. Absence of rheumatoid factor.
5. Presence of a high incidence of HL-A B-27
antigen.

Fig 28-Area or vasculitis (medium power) in the center of a

nerve trunk or the lower extremity. Note perivascular changes

in the nutrient artery of the trunk.

HL-A stands for Human Leukocyte Antigen,
and B-27 refers to its genetic locus on the chromo
some. All of this is an outgrowth of tissue typing
necessary in renal transplantation. We have known
for some time that ankylosing spondylitis patients
have a tendency to familial clustering, and there has
been a low incidence of spondylitis in American and
African blacks. In 1949, Toone reported studies from
the McGuire Veteran's Hospital indicating the pau
city of blacks who suffered from ankylosing spondy
litis.6 Baum later confirmed this in a larger group of
patients from a Veteran's cooperative study (Table
I).' Schlosstein et al, and Brewerton et al, had found
that there was a high correlation between the pres
ence of HL-A B-27 antigen in ankylosing spondy
litis-as high as 88% to 96%-and normal (8% in a
controlled Caucasian population) (Table 2 ). 8· There
9

Fig 38-Vasculitis and perivasculitis (medium power) of the
nccrot121ng vanety showmg obhterat1on <ii the artery of the
foot.
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Rheumatoid Factor Formation

lgG 75 Antigen
(Products of Self)

lgM 195

Auto-Antibody

22 S

RF Complex

Fig 4-Rheumatoid factor formation. Rheumatoid factors are
antibodies which react with other immunoglobulins to form a
rheumatoid factor complex in serum. 7S refers to sedimentation
constant in the ultracentrifugation analysis (Svedberg units).

are other diseases which have 8-27 as a genetic
marker. These include Reiter's syndrome, acute ante
rior uveitis, psoriasis with spondylitis, and others.
To better understand the immunological pro
cesses in developing a test such as the lymphocyte
microcytotoxicity test (LMCT), it is important to
understand the mechanics of the HL-A testing pro
cedure. The LMCT is performed approximately as
demonstrated in Figure 6.
I. Specific HL-A 8-27 antiserum from multi
parous women, or from those who have un
dergone numerous transfusions as a source of
developing 8-27 antibodies, is used.
2. The patient's lymphocytes to be tested for 827 antigen are prepared and mixed with the
antisera and rabbit complement in the cham
ber wells.

Test For Rheumatoid Factor
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3. The addition of trypan blue dye will stain the
interior of lymphocytes which have been
lysed by the antigen-antibody complement re
action. These lymphocytes are then counted
under inverted phase microscopy to deter
mine if the number of lysed cells is sufficient
to make a specific identification of 8-27 an
tigen.
One may conclude then that the HL-A 8-27
antigen is a genetic marker for the development of
certain diseases in which spondylitis seems to be a
common denominator. However, the part this
marker plays in the pathogenesis of the disease is
unknown.
Ill. Systemic Lupus Erythematosus (SLE).

There is no other connective tissue disease which
has evoked more interest among immunologists than
lupus; it might be labeled "the immunologist's de
light." The ability to diagnose this disease stemmed
from the Hargraves' LE cell test in 1948 through
various patterns of antinuclear antibody (ANA) test
ing, through the LE band test, and through the
"lumpy-bumpy" deposits in the glomeruli.
If one understands the basic concept of produc
tion of experimental serum sickness, which was so
well demonstrated by Dr. Frank Dixon with the for
mation of immune complexes, one might understand
more clearly the pathogenesis of such diseases as
glomerulonephritis, rheumatic fever, SLE, and per
haps even rheumatoid arthritis (Fig 7 ). '0 The parallel
between these findings in experimental serum sick
ness and human SLE and the occurrence of a wide
range of autoantibodies against nuclear and tissue
antigens, provides strong support for an immunolo
gical process in SLE. These antibodies include anti
DNA antibodies, anti-DNA histone antibodies, anti
ribonucleoprotein (RNP) antibodies, anti-Smith
(Sm) antibodies, and a host of others. The demon
stration of DNA and anti-DNA antibodies in the
TABLE I
Racial Aspects of Ankylosing Spondylitis•

Negative Positive
Fig 5-Test "ror rheumatoid factor. Rheumatoid factor complex
will a$glutinate either latex particles, human RBC or sheep RBC
when sensitized with IgG. In the square at lower right the
well of.the left shows a negative test and on the right a positive
test wioft latex irarticles.

I. Random study McGuire VA Hospital: 26 white. 3 black.
Toone 1949
2. Combined VA Hospital study, 301 patients: 10% black.Baum 1971
3. HL-A 27 absent in Black Africans.
4. HL-A 27 only 4% in Black Americans.
5. HL-A 27 present in 8 of IO Black American spondylitics.
*The above figures demonstrate the relationship of HL-A
27 and ankylosing spondylitis on Black Americans.
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TABLE 2
HL-A 27 in Rheumatic Disease Patients•
Presence of H L-A 27

Percentage

Source

Normal

119/1456

8%

Rheumatoid arthritis
Gout
Ankylosing spondylitis

10/119
6/66
35/40
72/75
25/33
26/50
9/156
6/44
10/14

8%
9%
88%
96%
76%
52%
6%
14%
71%

Russell. 1972
Brewerton. 197 3
Schlosstein. 1973
White. 1972
Schlosstein. 1973
Schlosstein. 1973
Schlosstein. 1973
Brewerton. 1973
Brewerton. 1973
Brewerton. 1973
White, 1972
Russell. 1972
Metzger. 1974

Condition

Reiter's syndrome
Acute anterior uveitis
Psoriasis

Psoriasis/spondyliti s

• A compilation of rheumatic diseases and H L-A 27 shows its strong association with ankylosing spondylitis. Reiter's
syndrome. and psoriatic spondylitis.

11 12

8-27 ASSAY
#I
Undiluted
B- 27 ontisero
Diluted
B-27 ontisero

#2

#3

0 0 0
0 0 0
+

Lymphocytes to be tested

+
Trypon Blue

( Positive test)

( Negative test)

Fig 6-Lymphocyte microcytotoxicity test for B-27 antigen.
Lymphocytes to be tested for B-27 antigen are added to each
of three donor wells of diluted and undiluted specific B-27 anti
sera. With addition of complement and t rypan blue dye, cells
will lyse and stain positively with blue dye if B-27 antigen is
present.

human kidney in SLE reinforces the concept that
SLE i, an example of an immune-complex deposition
disease involving autoantibodies. •
Prior to the widespread use of antinuclear an
tibody testing for the diagnosis of SLE, one relied
primarily on the demonstration of hematoxylin bod
ies in fixed tissue, or the presence of LE cells in the
serum. Hematoxylin bodies are globular masses of
nuclear material which stain blue with hematoxylin
and eosin (H & E) stain and are histochemically
identical with the inclusion body of an LE cell. Severe
vasculitis is the hallmark of SLE, and fibrinoid de
posits in vessels have been shown to be composed
chiefly of DNA, anti-DNA, and complement com
ponents. The use of various immunological tests to
determine the presence of ANA have taken the place
of the LE cell test in making the diagnosis of SLE.
The method used here is the indirect immunofluores
cent antibody test, which employs mouse liver cells as
the source of nuclear antigen. If antinuclear anti
bodies are present, various patterns of immunofluo
rescence will appear, depending on what type of an
tinuclear antibody is present in the patient's serum.
The patient's serum to be tested is added to the
mouse liver cells and will adhere to the nuclear an
tigen even when washed. When anti-human gamma
globulin, which is commercially prepared and stained
with fluorescin is added, a bright apple-green fluores
cence will appear in the preparation when viewed
under ultraviolet light (Fig 8). We have come to
recognize four different fluorescent staining patterns,
which may help in differentiating different patterns of
disease expression in lupus. These include the homo
geneous or diffuse pattern, indicating antibodies to
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ogist's disease-many types of autoantibodies are
present, which can be demonstrated by various im
munodiffusion and immunofluorescent techniques.
These autoantibodies are thought to play a specific
role in the pathogenesis of SLE, particularly where
there is renal involvement.
IV. Mixed Connective Tissue Disease (MCTD).
The introduction of the term speckled pattern of
ANA immunofluorescence and the presence of ri
bonucleoprotein and Smith antigens opens the door
to mixed connective tissue disease syndrome.
The clinical picture of MCTD reveals it as a
syndrome consisting of many of the features of the
connective tissue disorders including rheumatoid ar
thritis with arthritis and arthralgias and rheumatoid
factor. SLE with skin rashes and speckled pattern of
antinuclear antibody immunofluorescence, progres
sive systemic sclerosis with Raynaud's phenomenon
and thickening of the skin. and polymyositis with

A
single- or double-stranded DNA: the peripheral or
ring pattern, usually indicating the presence of anti
bodies to double-stranded DNA with active lupus
present, usually with renal involvement: the nucleolar
pattern, in which the nucleoli of the mouse liver cells
take the stain, can be found in patients with systemic
sclerosis or Sjogren's syndrome; and the speckled
pattern, which stains for ribonucleoprotein and has a
fibrillar appearance in the nucleus and is found in
mixed connective tissue disease syndrome. It should
be emphasized that these staining patterns and the
statements regarding them are generalizations and
should not be interpreted as explicit evidence in these
cases. Sometimes we see a mixture of patterns, which
may confuse the issue (Fig 9).
In some cases of SLE, where a drug such as
hydralazine or procainamide is suspected in produc
ing the LE phenomenon and antinuclear antibodies,
a hemagglutination test or agar gel precipitation test
using single- or double-stranded DNA may be used.
Antibodies to single-stranded DNA are usually pres
ent in drug-induced SLE, whereas antibodies to
double-stranded DNA may indicate active lupus with
renal involvement. The ANA test is superior to the
LE cell test in making a diagnosis in SLE because
only 75% to 90% of patients with active SLE will have
positive LE cell tests. Almost all patients with lupus
will have a positive ANA test.
The conclusion here is that SLE is the immunol-

8

Patient's

Serum

Fluoresce in
Anti yG

Fig 8-lndirecl immunoOuorescent staining for antinuclear anti
bodies. Mouse liver cells are used as the substrate for source of
nuclear antigen. The r,atien1s· serum (A) containing antinuclear

antibodies binds to the nuclei leaving a coating. After washing.
the preparation is incubated with an anti-human gamma globulin
(8) which hinds only al the site where antinuclear antibody is
bound. Nuclei exposed to SLE serum will fluoresce when ex
amined under the Ouorescence microscope.
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with nephritis

Ring

RNA

Nucleolar

SCLERODERMA
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Fig 9- Different patterns of ANA testing. Antigen, pattern of fluorescent staining, and clinical correlation in the four types of nuclear
antibody tests.

myopathy and muscle enzyme changes. In other
words, it is a "mishmash" of the connective tissue
diseases, but generally patients are thought to have a
better prognosis with this syndrome and as a rule do
not have severe renal or central nervous system
(CNS) involvement as those with systemic lupus.
Concerning the diagnosis of MCTD, Gordon
Sharp at the University of Missouri, who has done
much work in this disease, feels that a diagnosis can
be made if the clinical picture fits and one can demon
strate antibodies to extractable nuclear antigen
(ENA) which are RNAse sensitive. 13 Extractable nu
clear antigen is prepared from calf thymus cells con
taining mainly RNP and Sm antigens. This test is
performed either by an immunodiffusion technique
or by hemagglutination method, to demonstrate anti-

bodies to RNP and Sm antigens. RNP can then be
removed from either test system by the addition of
RNAse, leaving only Sm antigen if it is present. If a
precipitin band remains in the immunodiffusion dish
after RNAse is added, this is Sm antigen antibody
band, which may be present in SLE and may indicate
a poorer prognosis than in those patients with
MCTD (Fig 10). The hemagglutination test for RNP
and Sm antigen is very similar to the technique em
ployed in the tanned sheep cell test in rheumatoid
factor. ENA is added to tanned sheep cells to coal the
cells with RNP and Sm antigens. When the patient's
serum containing antibodies to ENA is added, agglu
tination results, indicating a positive test. If after
RNAse is added there is no agglutination and the
sheep cells fall lo the bottom of the tube, this in-
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ENA Test

8
Before RNAse

8

RN As�

8

§

After RNAse

Fig 10-Extractable nuclear antigen test (ENA): Precipitating Antibodies to RNP and Sm Antigens. ENA (RNP and Sm antigens)
in center well of agar gel before RNAse show precipitin bands with both MCTD and SLE sera. After RNAse is added lo center well
in figure on right bands for MCTD, sera are no longer present, leaving only Sm precipitin bands for SLE sera.

HEMAGGLUTINATION TEST
FOR RNP AND Sm ANTIGENS

Fig 11-Hemagglutination test for RNP and Sm Antigens. Row I
represents a positive ENA agglutination in a titer over 100,000
for MCTD: Row 2 demonstrates the effect after RNAse has
been added, identifying an RNAse-sensitive antibody, and the
red cells fall to the bottom of the well, concluding that this
serum contains RNP antibodies found in MCTD: Rows 3 and
4 are sera from a normal individual with negative ENA tests
before and after RNAse: Rows 5 and 6 represent SLE sera
which contain antibodies to ENA which are RNAse-resistant,
indicating no RNP to be present and Sm antigen accuunling
for the persistent agglutination. Control sera are in the column
on the right.

dicates that only RNP antibodies for MCTD are
present. If on the other hand the agglutination re
mains after RNAse is added, this would indicate
other antibodies, such as those to Sm antigen, are
present, as is seen in SLE. Titers over I: I 0,000 are
thought to be significant in the interpretation of this
test (Fig 11 ).
For a diagnosis of mixed connective tissue dis
ease, high titers of hemagglutination antibodies to
ENA and no antibodies to ENA after RNAse is
added are required. A speckled pattern on fluorescent
ANA test is another indication for the diagnosis.
In a group of 100 patients studied by Sharp et al,
74% had RNAse-sensitive ENA by hemagglutination
or immunodiffusion techniques, and had mixed con
nective tissue disease. 13 Of the 26% who were RNAse
resistant ENA patients, a large majority had SLE.
This group then was composed of those patients in
whom the immunodiffusion and hemagglutination
tests showed the presence of antibodies to Sm an
tigen.
One can conclude, therefore, that those patients
who demonstrated antibodies to ENA, which are
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R Ase-sensitive (RNP antibody), may have MCTD
and are less likely to have renal and CNS in
volvement and have a better prognosis.
Summary.

I. Rheumatoid factor can be identified in the
sera of certain patients with rheumatoid ar
thritis, is produced in synovial cells. and may
have a role in pathogenesis in so111e patients.
2. H L-A B-27 antigen is a genetic marker for
development of certain diseases in which
spondylitis is a common denominator: its role
in pathogenesis is unknown.
3. Systemic lupus erythematosus is an example
of antigen-antibody complement complex
deposi.tion disease. DifTerenl types of antinu
clear-antibody tests are associated with differ
ent patterns of disease expression.
4. Patients with antibody lo the ribonucleopro
lein component of extractable nuclear antigen
may have mixed connective tissue disease and
are less likely lo have severe renal and CNS
involvement.
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The Polymorphonuclear Neutrophilic
Phagocyte
GERALD L. MANDELL. M.D.
Professor of Medicine. and Head. Division of Infectious Disease. Department of Medicine. University of Virginia
School of Medicine. Char/011esvi//e, Virginia

Patients who have too few functioning mature
polymorphonuclear neutrophils frequently develop
fatal bacterial or fungal infections despite our best
efforts to prevent and treat those infections. Recently
new facets of white cell function which enable us to
better understand both normal and abnormal states
have been found. Several review articles about poly
morphonuclear neutrophils (also called neutrophils
and granulocytes-the latter term includes eosino
phils and basophils) have been published recently'-'
and the reader is referred to these for more compre
hensive coverage of the field.
Development and Deployment of Neutrophils.

Cells that have the potential to develop into the
polymorphonuclear neutrophil series or into the
monocyte-macrophage series are present in bone
marrow. Those destined to be neutrophils go through
a sequence of maturation steps lasting about two
weeks. The early developing cells have a very rigid
cell surface, are poorly motile, and cannot effectively
engulf foreign particles. As they develop, gran
ulocytes become progressively more flexible. more
able to ingest foreign particles, and more efficient at
phagocytosis and killing microbes.
Mature polymorphonuclear neutrophils are con
stantly released from the marrow into the circulation.
Their half-life in the blood is about six to eight hours.
After leaving the blood, polymorphonuclear neutro
phils migrate to the tissues where they may live for
several days before being destroyed. Neutrophils are
Correspondence and reprint requests to Dr. Gerald L. Man
dell. Division of Infectious Disease. Department of Medicine, Uni
versity of Virginia School of Medicine, Charlollesville, Virginia
22903.
MCV QUARTERLY 13(2): 57-59, 1977

destroyed by fixed mononuclear phagocytes in such
organs as the liver. spleen, lungs. and bone marrow.
and others are excreted in the fecal stream. Hundreds
of millions of granulocytes enter the bloodstream
from the marrow and leave the bloodstream for the
tissues each day. but only a small percentage of the
body's total number of granulocytes circulates in the
blood at any one time. This circulating pool contains
between 3% to 5% of the total granulocyte popu
lation. The vast majority of mature neutrophils are
extravascular in tissues. or waiting to be released
from the bone marrow. It is this latter pool that is the
source of most of the increased numbers of circulat
ing white cells in patients with acute bacterial in
fection. There appear to be separate regulators of
neutrophil proliferation. maturation. and release into
the circulation.
Morphology and Motility.

The mature neutrophil is about 12 to 15 microns
in diameter and contains a multilobed nucleus. The
characteristic of the cell reponsible for the name
"granulocyte" is the presence of multiple granules
containing enzymes and preenzymes in the cy
toplasm. Other organelles are less conspicuous and
very little in the way of ribosomal structure or mito
chondria can be seen. There is a large amount of
cytoplasmic glycogen which can be utilized as an
energy source. Both microtubules and microfilaments
can be seen in the cell in special preparations.
Neutrophils are actively motile when in contact
with a solid surface: they crawl rather than swim.
Motile polymorphonuclear neutrophils look very dif
ferent from cells seen on a stained blood smear. They
usually have a broad front with a thin edge of cy
toplasm (the lamellipodia) followed by a slowly ta-
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pering. roughly triangular-shaped body and a knob
like tail. Granules are not seen in the leading edge.
but granules do move in the cytoplasm of the cell
where they seem to travel in roughly-defined chan
nels. There is evidence to support the concept that
microtubules and microfilaments are responsible for
cell movement.
Phagocytosis.
After mature neutrophils leave the bone marrow
and enter the circulation. their mission is to leave the
vascular system and migrate to areas where they are
needed such as an area of infection or injury. In the
first step in this process. called margination. neutro
phils circulating through capillaries near the site of
injury become sticky and adhere to endothelial cells
lining small blood vessels. Anti-inflammatory drugs
such as aspirin and prednisone inhibit granulocyte
adherence. The phagocytes leave the blood vessels by
crawling through the junction between endothelial
cells. The neutrophils are then directed towards the
site of microbial invasion by chemotaxis. a process in
which factors from the region of microbial invasion
attract neutrophils towards the greatest concentra
tion of these factors.
After neutrophils have migrated to tissue in
vaded by microbes. they attempt to ingest susceptible
microorganisms and destroy them. The first step is
recognition of the microorganisms as foreign to the
phagocyte and a target for phagocytosis. With some
organisms high titers of specific antibody are required
for this recognition while in others the so-called "nat
ural antibody" or low level of antibody usually pres
ent in normal serum is enough to stimulate phagocy
tosis. The antibody itself may promote phagocytosis.
but usually the combination of antibody plus com
plement factors is optimum for promoting phagocy
tosis. Only immunoglobulins of the IgG class are
opsonic.
When a neutrophil engulfs a microbe. the lead
ing edge of the Jamellipodia makes initial contact
(Figure) and pseudopods are sent out. cupping the
microorganism. This cup closes by means of mem
brane fusion which results in the microorganism
being enclosed in a membrane-bound space. This
space. called the phagosome. is bounded by the ex
ternal cell membrane which becomes internalized in
the process. The energy for phagocytosis and loco
motion is derived largely through anaerobic gly
colysis. and cells are able to move and engulf organ
isms in an anaerobic atmosphere.

EUTROPHILIC PHAGOCYTE

4
Figure-A series of phase contrast photomicrographs of a human
polymorphonu(lear ncutrophil ingesting two clumps of Srrepto
coccu., pyogenes (L,riginal magnification. X 1200). Photomicro

graph h, James Sulli,an and Gerald Mandell.

Leukocyte Bactericidal Activity.
During and after phagocytosis. granules in the
cytoplasm move towards phagosomes which contain
ingested particles. The contents of the granules are
extruded into the phagosome as the granule mem
brane fuses with the phagosome membrane. The
phagosome. now containing lysosomal and other en
zymes from the granules. is called the phagolyso
some. Degranulation enables these potent enzymes to
contact ingested microbes in the phagosome without
exposing the cytoplasm of the neutrophil to the pos
sible deleterious effects of the enzymes. Granules
"disappear" from the cell during this reaction. hence
the term degranulation.
Along with the events described above. changes
occur in the metabolism of the neutrophil. the most
dramatic of which is a marked stimulation of oxygen
consumption. The products of this oxygen consump
tion are oxidized forms of oxygen such as superoxide
anion (0 2 ) and hydrogen peroxide (H 20,). both of
which possess antibacterial activities. The antibacte
rial activity of hydrogen peroxide is markedly en
hanced by the presence of myeloperoxidase and a
halide. In the phagolysosome containing the ingested
microbe one finds myeloperoxidase. hydrogen per
oxide. and a halide. which in concert can kill the
microorganisms. Bacterial death may be the result of
a reaction which culminates in oxidation or haloge-
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nation, or both, or vital structures on the bacterial
surface.
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Immunology and Diseases of the Kidney
WILLIAM F. FALLS, JR., M.D.
Medical Service. Vererans A dminisrrarion H ospiral, and Deparrmenl of Medicine. Medica/ Callege of Virginia,
Healrh Sciences Division of Virginia Commonwealrh Universi1y, Richmond, Virginia

The emphasis of this paper is the review of sev
eral aspects of renal disease which have immunologic
overtones and clinical relevance. The pathogenesis of
several subtypes of glomerulonephritis will be dis
cussed, the immunologic implications of amyloidosis
will be noted, and the relation between immune
mechanisms and tubulointerstitial disease will be men
tioned. The discussion will then be completed by an
analysis of the prognosis of the aforementioned renal
diseases, and by an attempt to place contemporary
therapeutic modalities in a proper perspective.
Before treating each of these subjects, it is worth
acknowledging the important contribution which
evaluation of renal biopsy tissue has made to our
understanding of the relation between immune mech
anisms and renal disease. The availability of fresh
tissue from biopsies in living patients has allowed
adequate evaluation by immunoAuorescent micro
scopy and electron microscopy (EM). Each of these
techniques has provided important and com
plementary information about the nature of fine
structural damage induced by immune mechanisms.'
Immune Complex

Disease.

Pro/ifera1ive G/omerulonephriris.

Figure I is an immunoAuorescent stain for lgG
in the glomerulus of a patient with acute post
streptococcal glomerulonephritis. A Auorescin
tagged antibody against lgG has been layered over a
quick-frozen biopsy specimen and become attached
to the lgG. The positive Auorescent lumps are
thought to represent deposits of antigen-antibody

Correspondence and reprint requests to Dr. William F. Falls.
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complexes adjacent to the capillary basement mem
branes and in the mesangium (the supporting stalk)
of the glomerulus. It is assumed that these histologic
abnormalities reAect the following series of path
ogenic events: an antigenic derivative of the strepto
coccus has entered the circulation: an antibody re
sponse has developed: soluble immune complexes
have been formed in a state of antigen excess: the
complexes have precipitated in the glomerulus: com
plement components have been fixed: and the com
plement cascade activated with resultant production
of inAammation and damage to the gomerulus. Un
der certain circumstances immunoAuorescent stains
may identify complexes containing lgM and lgA as
well as various components of the complement sys
tem and fibrinogen.'
Figure 2 is a light microscopic view of a glomer
u l us from another patient with acute post
streptococcal glomerulonephritis. This picture is the
light microscopic correlate of the immunoAuorescent
preparation described above. The features of a dif
fuse proliferative glomerulonephritis including swell
ing of the tufts. a marked increase in cellularity (pri
marily mesangial cells). occlusion of the capillary
loops. and an inAux of polymorphonuclear leu
kocytes are present. It is likely that the leukocytes
have been attracted by leukotactic factors released by
activation of the complement cascade.'
Figure 3 is an EM preparation showing part of
the ultrastructure of a glomerulus from the biopsy of
a patient with poststreptococcal glomerulonephritis.
The pathologic findings include fusion of the foot
processes of the epithelial cells and deposition of
large. electron-dense deposits adjacent to the sub
endothelial surface of the basement membrane. It is
thought that these deposits represent the immune
complexes which have been discussed above. PostMCV QU/\RTERL Y 13(2): 60-68. 1977
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Fig 1-lmmunofluorescent microscopic preparation (anti-lgG) or
a portion or a glomerulus from a patient with poststreptococcal
glomerulonephritis. Note the "lump-bumpy" pattern. (X 1500).

streptococcal glomerulonephritis is characteristically
associated with large "humplike" deposits in the sub
epithelial position, but this finding is not absolutely
diagnostic because a similar locus of depositon has
been noted in other immune-complex-mediated renal
diseases such as syphilis with nephritis.'
Subsequently, it will become evident that im
mune complexes may localize on either side of the
basement membrane. The reason a deposit may lo
cate in a given site (either subepithelial, sub
endothelial, or intramembranous) is not entirely de
fined. Current theory holds that the location of
immune-complex deposits may depend upon their
physical characteristics, with smaller deposits

Fig 2-Light microscopic preparation (H & E) or a portion or a
renal biopsy from a patient with diffuse prolirerative glomerulo
nephritis following a streptococcal inrection (X 200).
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Fig )-Electron microscopic preparation or a portion or a glome
rulus from a patient with acute poststreptococcal glomeruloneph
ritis. Note the large subepithelial electron-dense deposit. "hump"
( X 32.000).

(formed by combination of antigen with low affinity
antibody) localizing in a subepithelial site and large
complexes localizing subendothelially.' There is also
evidence to suggest that complement-binding sites
may be present in the region of the epithelial cell foot
processes.' Complexes which have fixed complement
prior to traversing the basement membrane may be
snared by attachment of complement with these re
ceptors.
Figure 4 is the light microscopic view of two
glomeruli from a patient with a staphylococcal albus

Fig 4-Light microscopic preparation (H & E} or a portion or a
renal biopsy rrom a patient with "shunt nephritis" secondary to
staphylococcal inrection. Note that glomerulus in the center and
the portion or the glomerulus at the lower margin both show
prolirerative changes ( x 200).
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Fig 5-Electron microscopic preparation of a portion of a glome
rulus from a patient with systemic lupus erythematosus and a

diffuse proliferative lesion by light microscopy. Note the large
subendothelial deposits (X 10.000).

infection of a ventriculojugular shunt which had been
made because of hydrocephalus. The lesion is a dif
fuse proliferative glomerulonephritis and could not
be distinguished from the poststreptococcal lesion by
conventional light microscopic or immunofluores
cent studies. Figure 5 is an EM study showing a large
subendothelial deposit from a patient with lupus er
ythematosus and proliferative glomerulonephritis by
light microscopy. The subendothelial region is the
favored site of deposition in lupus. 1 Figure 6 shows
the light microscopic appearance of a glomerulus
from a patient with focal proliferative glomerulo
nephritis. Note that segments of the glomerular tuft

Fig 6-Light microscopic preparation (H & E) of a portion of a
renal biopsy from a patient with systemic lupus erythematosus
showing a focal proliferative lesion (X 400).

appear to have normal cellularity and that the in
flammatory reaction is less severe than in the cases
noted earlier. lmmunofluorescent and electron mi
croscopic studies would show the immune deposits to
be less numerous and to have more of a mesangial
location than in the diffuse proliferative lesion. IgA
deposition is seen with greater frequency in the mes
angium in focal lesions. 1
After a review of the first six figures it is clear
that the classic light microscopic picture of pro
liferative glomerulonephritis, either diffuse or focal,
reflects a disorder of immune-complex deposition in
the region of the glomerular capillary basement mem
brane and mesangium. From observation of the path
ologic material it is also easy to envision that the
inflammatory process would lead to leakage of albu
min, red blood cells, and immunoproteins into the
urine with development of an "active" urine sedi
ment. The mediators of inflammation in proliferative
lesions are not well understood but are thought to be
released by activation of the terminal portion of the
complement cascade. 1 Serum levels of early-reacting
complement components and C, are frequently, but
not invariably, reduced in patients with immune
complex-mediated proliferative lesions. The antigenic
substances which may be involved in this type of
lesion are numerous and will be discussed below.

Membranous Glomerulonephri1is.

Another histologic pattern of renal involvement
that is almost certainly mediated by glomerular im
mune-complex deposition is membranous glomerulo
nephritis (Fig 7). Note that the only abnormality is
marked thickening of the capillary basement mem-

Fig 7-Light microscopic preparation (PAS) of a portion of a
glomerulus from a patient with membranous glomerulonephritis
(X 200).
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brane. Figure 8 demonstrates that the cause of the
basement membrane thickening is the presence of
numerous dense deposits along the epithelial border
of the basement membrane with projections of base
ment membranelike material interposed between the
deposits. Fusion of the epithelial cell foot processes
adds to the breadth of the capillary wall and probably
has been induced by the marked albumin leak which
most of these patients experience. lmmunofluores
cent studies show a fine granular deposition of IgG
and IgM as would be expected from the location of
the deposits on EM.' On occasion. complement com
ponents also may be identified in the glomerular ca
pillaries, but this occurs with much less frequency
and in a more scant distribution than in proliferative
lesions. Serum complement levels are usually normal
in membranous glomerulonephritis. The absence of
an inflammatory response may relate to the presence
of immune complexes which fix complement poorly,
or to an impotent complement system. As might be
expected, patients with the membranous lesion usu
ally develop a nephrotic syndrome and tend to have a
less "active" sediment than those with a proliferative
process.
Antigens Associated with Immune Complex Dis
ease.
There are a large number of disorders in which
antigen-antibody complex deposition is recognized or
suspected as being the cause of renal disease.' Ex
ogenous antigens, particularly drugs and foreign pro
teins, may induce an immune-complex glomerulo
nephritis with the appearance of either a proliferative

Fig 8-Electron microscopic preparation of a portion of a glome
rulus from a patient with membranous glomerulonephritis. Note
the numerous subepithelial deposits. ( x 15,800).
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or a membranous lesion. A number of bacterial or
ganisms including the streptococcus, staphylococcus,
pneumococcus, and treponema pallidum have in
duced a complex-mediated nephritis which is usually
proliferative in pattern. Plasmodium malariae may
cause either a proliferative or membranous nephritis.
It is suspected that numerous viral agents may incite
immune-complex-mediated renal disease. Both hepa
titis-B virus and the Barr-Epstein virus have been
clearly identified as providing the antigenic stimulus
for an immune-complex-mediated disorder. The for
mer has been incriminated as inducing proliferative
and membranous lesions as well as a generalized
arteritis.
Perhaps the best defined of all immune-complex
mediated renal diseases is that associated with sys
temic lupus erythematosus. It is clear that in this
disorder endogenous cellular antigen (DNA, RNA,
and numerous derivative substances) provides an in
exhaustible source of antigen for complex formation.
Diffuse proliferative, focal proliferative, and mem
branous nephropathy have been identified in patients
with systemic lupus.
Recently, considerable excitement has been gen
erated by the discovery of other endogenously-pro
duced antigens which may cause renal disease in man.
A derivative of tubular brush border has been identi
fied as the antigenic component of an immune-com
plex-induced membranous glomerulonephritis in pa
tients with sickle cell anemia.' The nephrotic
syndrome secondary to a membranous lesion has
been recognized in some patients with solid tumors of
the lung and colon: in a patient with the latter neo
plasm carcinoembryonic antigen has been identified
as part of the complex on the basement membrane.•
Immune-complex glomerulonephritis may be seen
with some frequency in patients with cryoglobuli
nemia, particularly those in whom there is a mixed
IgG-IgM cryoglobulin with rheumatoid factor activ
ity.•
After reviewing all of the known causes of im
mune-complex-mediated renal disease one is left with
an unrecognized antigen as the stimulus for the dis
ease process in most cases of the idiopathic nephrotic
syndrome. This includes patients with focal pro
liferative, diffuse proliferative, or membranous le
sions. The offending antigen is also unknown in such
syndromes as Wegener's granulomatosis and He
noch-Schonlein purpura. Within the next few years
the inciting antigens will be identified in many of
these disorders and may well prove to be viral agents.
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cross-reacts with pulmonary basement membrane
and is thought to induce the pulmonary as well as the
renal disease. The stimulus for production of anti
basement membrane antibody is uncertain, but dam
age to pulmonary or glomerular basement membrane
by viral agents or chemical irritants with uncovering
of hidden antigenic sites has been suggested as a
mechanism. 1 As might be expected, patients with an
tibasement membrane antibody disease and crescent
formation frequently have very "active" urine sedi
ments and may be nephrotic.

Fig 9-lmmunofluorescent preparation (lgG) from a portion of a
biopsy of a patient with antibasement membrane antibody disease.
Note the linear pattern of fluorescence (X 1500).

Antibasement Membrane Antibody Disease.
Figure 9 is an immunofluorescent stain showing
homogeneous linear deposition of IgG along the
basement membrane of the glomerulus. This pattern
is thought to represent the attachment of antibase
ment membrane antibody to some antigenic com
ponent in the basement membrane. The antibody is
usually lgG although linear deposition of IgM and
complement have also been described in some cases.
In many patients, circulating antibody can be demon
strated by allowing the patient's serum to react with
sections of normal human kidney. The mechanism
whereby deposition of antibasement membrane an
tibody leads to renal damage is uncertain, but that
severe damage can be induced is amply demonstrated
by Figure 10 which shows a proliferative lesion of
both the mesangial and epithelial cells. Proliferation
of the latter with crescent formation is apparently
induced by the leakage of large molecular weight
fibrin precursors into Bowman's space through tears
in the basement membrane. 1
An occasional epithelial crescent can be found in
virtually any type of renal disease, but involvement of
essentially the entire glomerular population is seen in
two circumstances: rapidly progressive glomerulo
nephritis and Goodpasture's syndrome. Many pa
tients with the clinical picture of idiopathic, rapidly
progressive glomerulonephritis and most patients
with Goodpasture's syndrome (lung hemorrhage and
nephritis) will display evidence of antibasement
membrane antibody as the cause of renal damage.
The offending antibody in Goodpasture's syndrome

Glomerulonephritis and Activation of the Alter
nate Complement Pathway ( Membranoproliferative
Glomerulonephritis).
In general terms. when the complement system is
activated in the disorders discussed above. it is prob
ably brought about by the classic pathway (C i � C,
� C, � C,). Recently. however. evidence has begun
to accumulate suggesting that activation of the latter
part of the complement cascade via the so-called
"alternate pathway" may be of importance in in
ducing renal damage. 1 Activation of the "alternate
pathway" has been noted in some cases of post
streptococcal glomerulonephritis. but the most pro
vocative evidence for a role of this pathway has been
observed in patients with the pattern of membrano
proliferative or mesangiosclerotic glomeruloneph
ritis.
West and his associates originally described a
group of children with heavy proteinuria: "active"
urine sediments: low circulating C, levels: light m1-

Fig 10-LighI microscopic preparation (H & E) from the renal
biopsy of a patient with antihascmcnt membrane antibody disease.
otc the marked crescent formation and interstitial inflammatory
reaction (X 80).
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croscopic evidence of cellular proliferation, increased
mesangial matrix, and a tendency to lobulation of the
glomerular tufts: glomerular C, deposition with little
or no accompanying IgG or lgM by immunofluores
cence: and a circulating activator of C, (C, nephritic
factor).• The patients were considered to be a unique
group and designated as having membranoprolifera
tive glomerulonephritis with hypocomplementemia.
Subsequently, it has been recognized that patients
with membranoproliferative lesions are not a homo
geneous group: and they have now been subdivided
into two groups, primarily on the basis of EM fea
tures. Type I patients show evidence of splitting and
reduplication of the basement membrane and have
electron dense deposits. The activation of early com
plement components and the infrequent demonstra
tion of circulating C, nephritic factor in this group
suggest the presence of a classic immune-complex
mediated disease. Type II patients, on the other hand,
show a marked homogeneous increase in density of
the glomerular capillary basement membrane with
out evidence of deposits (dense deposit disease).' Cir
culating C, nephritic factor is usually present and
early reactive complement components are normal.
The nature of the dense transformation of the base
ment membrane is uncertain and the pathogenesis of
this disorder remains to be defined.

Lipoid Nephrosis of Childhood (Nil Disease).

Another disorder which classically has been con
sidered with the glomerulonephritides is lipoid neph
rosis of childhood or nil disease. This is the most
common cause of the nephrotic syndrome in child
hood. The only recognizable histologic abnormality
in patients with this disturbance is fusion of the foot
processes recognizable on EM (Fig 11 ). The etiology
of this disorder is uncertain, but renewed interest in
the possibility of its being an immunologic disease
has been kindled by the discovery of a similar lesion
in several patients with Hodgkin's disease who have
the nephrotic syndrome. Since current thought sug
gests that Hodgkin's disease may be a T-cell distur
bance, it has been suggested that nil disease reflects a
disturbance of cellular immunity.•

Focal Segmental Sclerosis.

A subgroup of children with the idiopathic neph
rotic syndrome who do not respond well to the thera
peutic agents mentioned below has been described
recently. This group frequently has mild microscopic
hematuria as opposed to the children with typical nil
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Fig I I-Electron microscopic preparation of a portion of a renal
biopsy from a patient with ..nil disease.·· Note the normal appear
ing basement membrane. the absence of deposits. and the presence
of fused foot processes (X 14.000).

disease who show no "activity" of the urinary sedi
ment. Segmental sclerosis beginning in the juxtame
dullary glomeruli and progressing to become a dif
fuse generalized involvement with ultimate global
sclerosis has been identified in these children.

Amyloidosis.

Amyloidosis of the kidney is an interesting cause
of the nephrotic syndrome which, on clinical
grounds, may be confused with the glomerular dis
eases previously mentioned and which has a close
relationship to the body's immune systems. On light
microscopy the glomerular mesangium may appear
infiltrated with a homogeneous material and the
basement membrane may be thickened. Such a pat
tern may be confused with diabetic nephropathy or a
late stage of immune-complex-mediated nephropathy
which has led to significant sclerosis: staining with
Congo red and viewing the sections under polarized
light will demonstrate the typical apple-green
birefringence if amyloid fibrils are present. however.
The amyloid fibril also gives a characteristic appear
ance by EM as demonstrated in Figure 12.
Exciting recent work has provided a clearer un
derstanding of the nature of amyloid. The amyloid
fibrils seen in patients with B-cell dyscrasias, either
multiple myeloma or primary amyloidosis, are
thought to be composed of light-chain derivatives of
the paraprotein produced by the abnormal B cells.' 0
An entirely unique protein (AA protein) has been
identified as composing the amyloid of patients with
secondary amyloidosis related to chronic infection or
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familial Mediterranean fever. 10 The reason that these
different proteins have similar refractive properties
and give a similar appearance on EM relates to the
fact that they share the same beta-pleated arrange
ment of their amino acid components.
Tubulointerstitial Disease.

Investigation of the immunologic aspects of
tubulointerstitial disease has been overshadowed by
the tidal wave of studies evaluating the mechanisms
of immunologic glomerular damage. Interest in the
interstitium has been rekindled, however, by the dis
covery of an association between the ingestion of
certain drugs and the development of interstitial
nephritis. It is now evident that a molecular moiety of
several members of the penicillin family may act as a
hapten, combine with an endogenous protein to
make a complete antigen, stimulate an antibody re
sponse, and ultimately result in precipitation of im
mune complexes in the region of the tubular base
ment membranes with incitement of a diffuse
interstitial inflammatory reaction." Autoantibodies
to tubular basement membrane have also been dem
onstrated and incriminated as the cause of interstitial
infiltration in lupus erythematosus, the transplanted
kidney, and the crescentic disease of Goodpasture's
syndrome and rapidly progressive glomerulonephritis
(Fig 10).' Studies in animals have suggested that
chronic pyelonephritis may be perpetuated by cellu
lar immune mechanisms originally activated by the
release of antigenic substances from tissues damaged
by invading pathogenic bacteria.'
Prognosis and Treatment.

Having reviewed the current thoughts about the
pathogenesis and histologic appearance of immuno
logically related renal disease, we ought now to at
tempt to apply this information in a fashion that will
be beneficial to a given patient. Such application
is practical in two major areas, prognosis and treat
ment. The importance of a renal biopsy in obtain
ing tissue for evaluation is obvious. Its importance in
obtaining practical prognostic and therapeutic infor
mation which will help the patient is variable. For
example, a renal biopsy is not likely to be helpful in
the management of the patient with obvious inter
stitial disease as manifested by leukocytes and a rela
tively scant amount of albumin in the urine. If the
disease is drug induced, it will probably resolve spon
taneously with discontinuation of the offending agent.

Fig 12-Electron microscopic preparation of a portion of a glome·
rulus showing amyloid fibrils (X 24.000).

It is among patients with an unexplained nephrotic
syndrome that evaluation of an adequate renal
biopsy is most helpful.
Prognosis.

Patients with focal proliferative glomerulone
phritis. lipoid nephrosis. and membranous glome
rulonephritis have a relatively good prognosis either
treated or untreated. Lupus patients with a focal
proliferative lesion may live for years without show
ing evidence of deterioration in renal function. Many
children with nil disease undergo a spontaneous re
mission and when deterioration in function occurs. it
usually progresses very slowly. Patients with drug
related or tumor-related membranous nephropathy
may have remission of their disease with removal of
the offending antigen: those with an idiopathic mem
branous lesion, or lupus and a membranous lesion.
may spontaneously remit or remain nephrotic with
an unchanged creatinine clearance for years.'
On the other hand. patients with diffuse pro
liferative lesions unrelated to a specific infecting or
ganism, particularly those with lupus erythematosus.
have a poor prognosis. Most patients with antibase
ment membrane antibody disease and marked cres
cent formation will reach the terminal stage within
two years.
Patients with membranoproliferative glomerulo
nephritis tend to have an intermediate prognosis with
most showing progressive deterioration in renal func
tion to its terminal stage in 5 to 12 years.' Amyloid
patients and patients with segmental sclerosis also
demonstrate an intermediate prognosis.
As knowledge accumulates. we may feel obliged
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to perform a biopsy on every patient with chronic
renal disease who is progressing toward its terminal
stage in order to determine his or her ultimate can
didacy as a transplant recipient. Antibasement mem
brane antibody disease, membranoproliferative
glomerulonephritis, and focal segmental sclerosis
have been recognized as recurring in grafted kidneys,
ultimately leading to their failure. Indeed, it is now
considered inappropriate to transplant a patient with
antibasement membrane antibody disease if circulat
ing antibodies can be demonstrated in his or her
serum. 1
Treatment.
Much has been written about the treatment of
immunologically related renal diseases. Unfortu
nately, except for the management of two disorders,
nil disease and Wegener's granulomatosis, there is
little agreement and much bias about specific treat
ment. Diuretics are of great symptomatic value in
edematous states but have no effect on basic path
ogenic mechanisms. The agents which have been used
as possible inhibitors of immune mechanisms include
corticosteroids, antimetabolites, and alkylating
agents. Each of these drugs has significant toxicity,
particularly when used over a prolonged period, and
their modes of action remain uncertain. The natural
history of many of the immunologically related renal
diseases is variable and capricious. Consequently,
controlled studies, involving numerous patients and
extending over a long period of time, are needed to
establish the efficacy of any drug regimen. These
studies have not been done. Outlined below is a per
sonal assessment of the state of the art of immuno
therapy in renal disease.
As already mentioned there seems to be uniform
agreement that therapy is effective in those patients
with nil disease and those with Wegener's gran
ulomatosis. In lipoid nephrosis the administration of
corticosteroids will enhance the rate of remission,
and the duration of remission after relapse can be
prolonged by supplementing the steroids with cy
clophosphamide or chlorambucil. Nil disease in
Hodgkin's disease will subside with treatment of the
lymphoma. Cyclophosphamide is effective in produc
ing a sustained remission in the renal disease of
Wegener's granulomatosis, a disorder which was for
merly uniformly lethal.12
Treatment in a patient with immune-complex
mediated diffuse proliferative or focal glomerulo
nephritis is most effective if it can be directed at
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eradication of a recognizable inciting antigen. Ob
viously, this is most successful if the antigen is de
rived from an infectious agent such as a staphylococ
cus or a spirochete. If the antigen cannot be removed
as in lupus erythematosus, one must carefully weigh
the potential benefits of therapy against the possi
bility of significant drug toxicity. It is my impression
that most authorities would tend not to treat a focal
proliferative lesion in lupus but would be aggressive
in the management of a patient with a diffuse pro
liferative lesion. In the latter case, one might use a
combination of steroids and either azothioprine or
cyclophosphamide in doses sufficient to return sero
logic indicators of disease activity such as C, levels or
anti-DNA antibody levels to normal. 13
The management of membranous glomerulo
nephritis of either the idiopathic type or that asso
ciated with lupus erythematosus is equally per
plexing. Controlled studies done in Great Britain in
the 60s suggested that no therapy was effective in the
idiopathic membranous lesion." However, recent un
controlled retrospective analysis 16 · and an ongoing
American cooperative study 17 suggest that prolonged
steroid administration may be helpful.
Therapy for patients with crescentic disease has
included steroids, azothioprine, cyclophosphamide,
and anticoagulation agents. Isolated cases treated
with these agents have shown good responses, but
there have been no controlled studies to substantiate
this fact. Steroids have been advocated as being of
value in membranoproliferative lesions, 1• but here
again there have been no comparisons with a com
parable untreated population.
There seems to be no specific treatment for am
yloidosis. However, amyloid deposition may be in
hibited by treatment of an underlying myelomatous
state or by correction of a smoldering infectious proc
ess.' Success has been reported recently in reducing
proteinuria in amyloid disease secondary to familial
Mediterranean fever by the administration of colchi
cine.'0
16

Summary.

The relation between the immunologic systems
and renal disease has been brieAy reviewed and sev
eral pathogenic immunologic mechanisms have been
correlated with the histologic pictures which they
produce; this information has then been related to
contemporary thoughts about prognosis and therapy.
Much has been learned, but there is obviously much
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more to be done, particularly in the areas of pre
vention and treatmenf.
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Cancer: The Great Challenge for Immunology
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The existence of immunity to cancer was postu
lated by the eminent scientists who helped to estab
lish the discipline of immunology. In 1907 Clowes
suggested that human resistance to cancer resulted
from what we. today call "immune surveillance." 1•
During the ensuing 70 years the results obtained from
experimental animal cancers and human cancers have
greatly influenced the palatability of tumor-immunity
theories.3·' Early optimism that immunity to cancer
could be specifically induced waned and almost dis
appeared when it was demonstrated that the rejection
of cancer transplants resulted from transplantation
immunity and not tumor immunity. A sustained
wave of enthusiasm for immunity to cancer appeared
after demonstrations that inbred animals could be
immunized to cancers arising in the inbred strain.5·
The objective of this paper is to try to reexamine
many aspects of cancer immunology and to shift the
emphasis currently placed on some of these aspects
into other areas with greater potential for clinical
application. This is not meant to be one of the numer
ous reviews of cancer immunology but rather a bal
anced presentation of alternative viewpoints which
will ultimately tilt toward my viewpoint.
The plan for the paper is as follows: ( I ) the types
of contributions immunology has made to mankind
will be briefly reviewed: (2) a general theory describ
ing cancer immunity with some supporting evidence
will be presented not once but twice: (3) finally the
current status of immunotherapy of human cancer
will be briefly mentioned.
Co111ribwions o/Im111uno/ogy.
A review of the major contributions of immu
nology to humanity should offer a preview of what
can reasonably be expected from future contributions
2
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of this field to the understanding and control of can
cer. The trademark of immunology is prevention of
disease by immunization. With the discovery of anti
biotics and their use in tissue cultures. a fresh attack
upon many viral infections became possible. In the
past two decades. the cultivation of viruses in vitro
has resulted in the elimination of epidemics of po
liomyelitis: infection with measles virus is less com
mon. Where the human is the sole host and reservoir
of an infection. immunization may lead to the eradi
cation of a disease. This appears to be the attainable
goal in smallpox where we are at the threshold of its
eradication by intensive immunization and epidemio
logic field work.
While the trademark is immunization. the work
horse of immunology is serology. lls use in diagnosis
and blood banking alone are of critical importance to
the functioning of our hospit<c1ls. A strike of all tech
nicians doing serologic tests would paralyze our
health care system. In addition to its diagnostic con
tributions. immunology provides an important un
derstanding of the pathogenesis of disease.
A relatively new but potentially major contribu
tion is in predicting susceptibility to disease. The
association of certain transplantation antigens with
specific disease states may be the forerunner of sero
logic identification of disease-risk factors.
When one turns to the role of immunology in
therapy. the work seems harder and the results hardly
optimal. This view is not meant to belittle the value of
replacement therapy in certain immune deficiency
diseases, or of immunosuppressive therapy in pre
venting transplant rejection: rather it is intended to
point out that cancer immunology is much, much
more than immunotherapy.
Grneral Frn1ures of" /111111uni1y 10 Cancer.
All cancer immunology is inextricably linked to
the existence of an antigenic difference between the
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cancer cell and its closest normal "relative'' cells.
Without such a difference, immunology has no entry
into the cancer field.
The transformation of a normal cell to a cancer
cell is probably accompanied by an antigenic change.
This transformation may occur frequently in all of us.
With a properly functioning immune system, the an
tigenic change or changes in the cancer cells are rec
ognized and following recognition an effective anti
cancer cell immune response destroys the malignant
cells. Appearance of clinical cancer is thus considered
to be a prima facie case of a failure of normally
operating immunologic mechanisms.
Ei;idence Supporting Immune Surveillance.

Origins for cancer antigens are not hard to find.
Oncogenic viruses are obvious sources of extraneous
antigenic material incorporated into cancer cells.
While no human oncogenic virus has been clearly
identified, several viruses are viewed with suspicion.
Chemical compounds play an important role in the
initiation of human cancer, and for many years these
carcinogens included many compounds that are also
mutagens. Recently a bacterial test for detecting
chemical mutagens has shown that almost every
known chemical carcinogen is either a mutagenic
agent or is metabolized to a mutagen.' Chemical
carcinogen-induced changes in the bases of deoxyri
bonucleic acid (DNA) can result in the synthesis of
abnormal. that is, antigenic, proteins. Similarly.
physical agents such as ultraviolet and x-irradiation
are also known carcinogens and mutagens.
Amongst the wide variety of human cancers, an
impressive list of cancer-associated "time and place"
antigens have been detected.•- 1 0 The carcinoembry
onic antigen of the gastrointestinal tract. alpha-feto
protein. chorionic gonadotropin, antidiuretic hor
mone. and parathormone are examples of normal
product made by cancers that are either abnormal
for postnatal life or for that type of cell.
As we move to consider the evidence for the
existence of immune cancer-rejection systems, we
need to rely on negative observations. It is impossible
to demonstrate that we are cancer-free as a result of
active recognition and destruction of small clones of
cancer cells. but strong circumstantial evidence
points to such immune mechanisms. Patients who are
recipients of organ transplants have a high risk of
subsequently developing a malignant disease 11 ·12 :
these patients are estimated to be at least 25 times
more likely to develop cancer than the normal popu
lation.

An additional group of patients at high risk for
developing cancer are those individuals with im
munodeficiency diseases. From 5% to I 0% of patients
with sex-linked agammaglobulinemia, combined im
munodeficiency disease, Wiskott-Aldrich, or ataxia
telangiectasia will develop clinical malignant disease.
Further but less definite indications that we are pro
tected by immune mechanisms include the observa
tions that chemical carcinogens may be immunosup
pressive,1• the claims of cutaneous anergy in patients
with neoplastic disease, 1'- 1' and the frequently stated
view that patients with cancer have an increased sus
ceptibility to infection. 1 •
The last element to be considered in the con
struction of an immunologic lattice for the contain
ment of cancer is the alteration of the course of
cancer by immunologic methods-immunotherapy.
Attempts to stimulate a specific immune response 1'
and to stimulate the entire immune response by
agents like bacille Calmette Guerin (BCG )'0 have
been extensively performed. In 1971, a comprehen
sive review was published by Yashpie,'1 and the re
port of a conference entitled. "lmmunotherapy of
Cancer: Present Status of Trials in Man," held in
Washington in October, 1976, is to be published.
How effective is immunotherapy for human can
cer? It is important to realize that the concept of the
"proof of the pudding is in the eating" is as much
determined by how hungry one is as by the quality of
the pudding. Rather than enthuse about immuno
therapy, I prefer to accept its present meagre results
as a challenge to reexamine our entire position. I will
also consider immunology with respect to prevention,
pathogenesis, early diagnosis, treatment monitoring
aids, and immunotherapy.
Prevention of Human Cancer by Vaccines.

An extensive review of the possibilities in this
area was recently published." At least two major
obstacles need to be overcome before vaccines for
human cancer become a reality. First and foremost
the link between a human virus and the cancer it
causes needs to be firmly established. Then the virus
can be developed into a vaccine-living, killed. or
subunit. The second problem is to determine who
should receive the vaccine. Since the incidence of any
one kind of carcinoma is relatively low, methods are
needed to identify the high-risk groups. Where the
prevalence of a carcinoma may be 5 to 10 persons per
100,000, it would be unacceptable to try to immunize
the whole population.
Where a viral-associated neoplasm behaves like
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a communicable infectious disease, a vaccine could
be very helpful. Such a situation exists in the poultry
industry. A DNA herpes-like virus (Marek's disease
virus) is manufactured into a fully infectious form in
the feather follicle of the chicken. In addition this
virus spreads within the chicken and causes a fatal
lymphoreticular disease; it also spreads amongst
chickens and can wipe out a flock. An effective vac
cine has been prepared from an apparently harmless
herpes virus of turkeys. This vaccine protects the
chickens against Marek's disease!•
The Pathogenesis of Cancer.
Immunologists searching for human cancer anti
gens have made an astounding, although largely ig
nored, contribution to our understanding of the
pathogenesis of cancer. Despite years of search by
numerous competent investigators, a cancer-specific
antigen has not been isolated for any human cancer.
Although the search for cancer-specific antigens is
too important to be abandoned, the possibility that
specific cancer antigens do not exist must be faced.
Instead of cancer-specific antigens, cancer-associated
antigens have been found. Some of these antigens are
considered time antigens. A cancer cell makes fetal
alkaline phosphatase, or a fetal pyruvate kinase
isozyme, or embryonic antigens, or structures such as
alpha-fetoproteins; place antigens also are made.
Thus a variety of normal hormones are made by
malignant cells derived from cells that have ceased
making these products. Frequently these hormones
produce symptoms in the patient, a paraneoplastic
syndrome. Were we to have the full catalog of normal
gene products made from conception to maturity, it
is possible that a time or place antigen or both could
be associated with every human cancer. The finding
of time and place cancer-associated antigens instead
of cancer-specific antigens fits in with an intriguing
new concept of the pathogenesis of cancer;• which as
its essential feature regards cancer as a programming
error. Carcinogenesis is not a mutation to new struc
tures but rather a reactivation of genetic programs
that were terminated a long time ago. In this view
viruses, chemicals, and physical agents act by going
· into the "old book" section of the cell's DNA library
and activating something long dormant.
It is possible to estimate the percent of the infor
mational DNA that is being actively transcribed by
cells. There is no difference in the amount of DNA
active in the blastula phase, the gastrula phase, or the
adult cells. About 3% of the DNA is being used, but
the 3% used in the gastrula phase cells is not identical
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to the 3% used by the blastula cells. Thus normal
development consists of the orderly and sequential
production and elimination of portions of the DNA
program.
Can programs be initiated? Dr. Ruddy referred
to androgen treatment of hereditary angioedema.
The administration of an androgen leads to synthesis
of a significant amount of a protein necessary to
inhibit spontaneous activation of the complement
system; other examples exist, perhaps the best being
the reactivation of the information locked up within a
cell nucleus as reported by Gurdon. 2' Trans
plantation of organelles produced striking results
when the nucleus of a fertilized frog ovum was re
moved and replaced by the nucleus of a mature frog
muscle cell. The microsurgically treated cell was then
restored to its proper environment, and development
of the ovum resulted in the formation of a tadpole.
All the information for this development was uncov
ered in an orderly fashion from the mature nucleus of
a differentiated cell. Similar results have been ob
tained when the nucleus from a mature frog lym
phocyte was transplanted into an enucleated ferti
lized frog ovum.
Our society seems to have more difficulty in for
mulating the correct questions than it does in provid
ing the answers to these questions. The finding of
several cancer-associated antigens emphasizes that
cancer immunologists must continue to examine
serologically the early stages of development with the
objective of identifying additional tumor-associated
antigens that in turn may be critical in establishing
valid early diagnostic tests for cancer.
The Nature of the Immune Defect in Cancer.
The failure to demonstrate an effective immuno
therapeutic method requires that the defects in the
immune surveillance and rejection system be exam
ined again with respect to cancer.
Does the patient who develops a carcinoma of
the lung, or breast, or stomach or other organs have a
defect that is applicable to the recognition and reac
tion to many antigens or is the defect confined to the
antigen or antigens associated with that particular
cancer? This is not a trivial question since the direc
tion for future immunotherapy depends on the an
swer. Arguments in favor of a broad defect are the
high incidence of neoplasm in transplant patients and
in those with immune deficiency diseases, but the
interpretation of this evidence is not decisive. Cy
totoxic immunotherapy is not exclusively immuno
suppressive. It may interfere with DNA repair mech-
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anisms which if unchecked could cause malignancy as
seen in xeroderma pigmentosa. 26 These patients have
a very high incidence of neoplasms of the skin, and
severe impairment of the ability to repair the damage
in DNA caused by ultraviolet irradiation. Many of
the drugs used in immunosuppression may also inter
fere with DNA repair mechanisms.
The evidence suggesting that there is no broad
immune defect in cancer patients is drawn from the
incidence of infection in patients with solid neo
plasms. Since the earliest days of immunology, in
fection has pointed to the areas where immune de
fects exist, and it is unusual to see clinically
significant immune defects without concomitant fre
quent infection. Indeed the defects may be so subtle,
as in sickle cell disease, that increased susceptibility
to infection is recognized long before the nature of
the immune defect is discovered.
Contrary to general opinion, infection is not a
common problem in the patient with solid cancers,
although infection certainly occurs when large masses
obstruct a passageway or become necrotic. If exten
sive chemotherapy renders the patient gran
ulocytopenic, or if large doses of steroids are given,
infection occurs, but under other circumstances, in
fection in a non-terminal cancer patient is rare. Ac
counts of infection in cancer patients are pre
dominantly those of patients with leukemia,
lymphoma, and myelorna. Of 93 patients with asper
gillosis, only 14 had solid tumors." Of these, 11 were
receiving steroids and nine were receiving cytotoxic
drugs. Another recent report'" shows that 31 of 35
patients treated for infection with sulfamethoxazole
trimethoprirn had hematologic malignancies; so it
goes with all reports of infection in cancer patients.
It appears to me unlikely that the overwhelming
majority of patients with solid tumors have a large
blind spot in their immune system. Skin testing for
anergy, counting T and B lymphocytes, and stimu
lating lymphocytes with mitogens can probably be
safely discontinued or replaced by looking for the
real defect in the immune system in cancer patients.
This leads to the second question. How does an
antigenic cancer escape detection') The answer to this
question is beset with technical difficulties. The re
ports of two workshops 29· designed to evaluate the
results of in vitro cytotoxicity tests for cancer cells are
gloomy. More emphasis needs to be placed upon
technical improvements in the culturing of cancer
cells and in determining their in vitro susceptibility to
antibody and to lymphocytes and macrophages.
30

Our understanding of this area is intimately tied
to our efforts in human cancer immunotherapy. An
outline of how a cancer breaks through or may break
through is of value even though it is purely specula
tive. Early studies in malignant melanoma" stressed
the importance of humoral antibodies. Patients with
localized melanoma were reported to have antibody
which reacted with melanoma cells while patients
with disseminated melanoma generally lacked these
antibodies. Using in vitro techniques, the Hellstroms
demonstrated a more complex Trojan Horse type of
immunologic arrangement" in which lymphocytes
from a cancer patient could destroy in vitro cancer
cells removed from that patient. This cellular immune
reaction could be inhibited by antibody present in the
serum of that cancer patient and from these observa
tions a dual immune system was formulated-an
tibody could protect the cancer, and cellular immun
ity could destroy the cancer. Further modifications
have been made in both the serum and cellular as
pects, but the basic premise remains that the destruc
tion or growth of a cancer depends upon the relative
strengths of two types of immune reactions. This
point should be returned to in considering the results
of immunotherapy.
Immunology and Early Diagnosis of Cancer.
Early diagnosis implies identification of the pres
ence and location of malignant cells at a time when
curative treatment can be performed. Today none of
the immunologic tests for cancer-associated antigens
are sensitive and specific enough to meet this require
ment.
The nature of the immunologic tests for cancer
associated antigens is qualitatively different from
tests measuring levels of liver enzymes or bone en
zymes. In the latter tests, it is unlikely that a small
mass could raise the level of normally present en
zymes to an abnormal level; that is, there is a high
background of normal activity that obscures the sim
ilar activity of the neoplastic cells. In the immuno
logic tests, the search is for fetal antigens in which the
background levels should be low. This is an area in
which future progress may produce valuable results.
f 111111unologic Treatment Monitoring A ids.
Three radioimmunoassay tests are currently of
great value in the management of patients with cancer.
The carcinoembryonic antigen (CEA) test is of
great assistance in management of some patients with
colorectal carcinoma. Where the level is elevated pre
operatively, the postoperative levels are useful in as-
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sessing the recurrence of disease and the response to
therapy. We are not recommending adjuvant post
operative chemotherapy, but an elevation in the CEA
is one indication to search for the location of the
recurrence and for initiation of therapy.
Radioimmunoassay of chorionic gonadotropins
has long been known to be essential in planning the
treatment of choriocarcinoma. The radio
immunoassays for alpha-fetoprotein and for the B
subunit of chorionic gonadotropin add a major new
dimension to our management of patients with testic
ular cancer. Decisions about starting chemotherapy
and the selection of the chemotherapy drugs used are
greatly influenced by the results of these immunologic
tests.
lmmunotherapy of Cancer.
I have not allotted much space to the analysis of
cancer immunotherapy. Many techniques-some
simple, some complex, and some very ingenious-are
being used to either treat human cancer or to prevent
its recurrence.
The experimental studies of BCG immunization
in the guinea pig" illustrate the potential value and
the limitations of immunotherapy. In this system,
injection of living Mycobacterium bovis BCG into the
tumor residing in an animal capable of developing
cellular reactivity to BCG, and at a time when the
tumor is small, results in a marked decrease in the
number of tumor-transplantation takes. Many exper
imental animal systems carefully designed to demon
strate an effect of immunotherapy have been pub
lished. The literature on human cancer
immunotherapy trials is enormous; its abundance
makes it difficult to discount. In my view the effec
tiveness of any immunotherapeutic procedure in hu
man cancer has yet to be demonstrated. There is great
interest in studying the results reported at the confer
ence "lmmunotherapy of Cancer: Present Status of
Trials in Man."
Predicting the future course of immunothera
pists is hazardous. The mood or moving spirit seems
to indicate a great disenchantment with BCG and its
allied products. A shift to Corynebacterium parvu/um
is underway, but it is probably too toxic to gain wide
acceptance. The newest bacterial entry is the pseudo
monas vaccine. The direction seems to be to go
through Bergey's Manual, a task that could involve
generations.
Ironically BCG is being rejected as uncritically
as it was accepted. If we are to be able to interpret an
immunotherapy trial properly, we need to know

more than the change in size of a cancer mass or the
duration of survival. We need measurements of the
changes in the levels of antitumor blocking antibody,
unblocking antibody, and cellular cytotoxicity and
cellular suppression. With this information we can
learn how to stimulate selectively the portion of the
immune response that destroys cancer without stimu
lating the immune response that aids cancer.
Conclusions.
Immunology provides a valuable tool as a treat
ment monitoring aid in many cancers.
The likelihood of an effective cancer vaccine is
remote and requires identification of both an onco
genic virus and a susceptible subgroup.
The failure to find cancer antigens and the abun
dance of cancer-associated antigens suggest that can
cer may be a programming error and potentially re
versible.
Immunology is likely to provide better and effec
tive early diagnostic tests.
The major need in immunotherapy is laboratory
support to measure the effects of therapy upon anti
tumor immune response.
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Introduction.
We have recently seen two patients with cystic
medial necrosis of the aorta. The first patient died of
a dissecting aneurysm of the thoracic aorta. At au
topsy. classical Hashimoto·s thyroiditis was discov
ered. The second patient died of a rupture of the
ascending aorta. At autopsy. chronic thyroiditis was
seen with multiple large germinal centers and diffuse
fibrosis. Neither patient was clinically suspected of
thyroid dysfunction although the second patient had
had a partial thyroidectomy in the remote past.
The association of dissecting aneurysm and post
thyroidectomy myxedema in three patients was re
ported many years ago.' Autoimmune thyroiditis
with symptoms of hypothyroidism and dissecting
aneurysm have also been observed together.' It has
also been reported that aortic aneurysm appears to be
significantly more frequent in myxedematous patients
than in other hospitalized patients.3 The underlying
theme in these clinicopathological correlations ap
pears to be that hypothyroidism may cause weak
ening of the aortic wall. This report is meant to focus
attention on this possibility and point out that sub
clinical cases of hypothyroidism may also involve the
aorta.
Case Report I.
A 76-year-old black woman who had a history of
mild hypertension was brought to the emergency
room because of sudden low back pain and "spells"
earlier the same day. Her vital signs were a pulse of
Corrcspon<lcn<.:c and reprint requests to Or. William S. Wi!'-c,

Department or Pathology. Huron Road Hospital. 1.\951 Terrace

Road. Cleveland. Ohio 44112.
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68/min. blood pressure 120/84 mmHg. respiration
44/min. She had prominent epigastric aortic pulsa
tions. A chest x-ray showed cardiomegaly and a wid
ened mediastinum probably due to the thoracic
aorta. She had multiple PVB's on her elec
trocardiogram. She suddenly became unresponsive
after her physical exam and died.
The autopsy was performed 17 hours after
death. There was a dissecting aneurysm of the tho
racic and abdominal aorta and a hemopericardium.
The aorta showed mild to moderate atherosclerosis,
but the thoracic and abdominal aorta were grossly
pliable. Marked cystic medial necrosis was seen with
hematoxylin and eosin staining and was confirmed by
the significant metachromasia seen with the aldehyde
fuchsin and toluidine blue stains. The heart weighed
450 gm and the left ventricle was 2 cm thick. Moder
ate atherosclerosis of the major coronary arteries was
present and the myocardium had moderate diffuse
interstitial fibrosis. The thyroid had a diffuse lym
phocytic infiltrate together with germinal centers and
Hlirthle cell change. The morphological criteria for
Hashimoto·s thyroiditis were therefore fulfilled.
Case Report 2.
A 55-year-old black woman experienced the sud
den onset of severe sharp midepigastric pain while
ascending a flight of stairs and immediately lost con
sciousness. She was brought to the emergency room
in a state of shock. Arter admission the patient had
generalized seizures followed by episodes of ventricu
lar tachycardia and ventricular fibrillation. She re
sponded to resuscitation at first but later developed
cardiac arrest and died. She had no history of hyper
tension and had been taking no medications. Ten
MCV QU/\RTERLY 1.1(2): 76-77. 1977
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years prior to this episode she had undergone a par
tial thyroidectomy for thyroid nodules.
An autopsy was performed four hours after
death. A large rupture in the wall of the ascending
aorta extended into the adventitia of the aorta and
pulmonary arteries. A hemopericardium containing
100 cc of blood and clot was present. The abdominal
and thoracic aorta were markedly atherosclerotic.
Marked cystic medial necrosis was seen in the ascend
ing aorta and significant metachromasia was demon
strated with the toluidine blue stain. The heart
weighed 450 gm and showed left and right ventricular
hypertrophy. The left anterior descending coronary
artery was 50% occluded by atherosclerosis within I
cm of the coronary ostia. Scattered areas of early
myocardial necrosis were seen microscopically. The
thyroid was small and firm. and one lobe had been
previously removed. A marked chronic thyroiditis
composed of diffuse lymphocytic infiltration. promi
nent germinal centers. and scarring was present. but
there was no Hlirthle cell change. The partial thyroi
dectomy done ten years previously showed the same
histologic pattern. A single sigmoid kidney was pres
ent on the right as a result of crossed renal ectopia
with fusion.

Discussion
The two patients in this report both had cystic
medial necrosis of the aorta and died as a result of
complications of the weakened aortic wall. Both pa
tients were hypertensive based either on history or on
the autopsy findings of cardiomegaly and left ven
tricular hypertrophy. Systemic hypertension is often
present in patients dying of dissecting aneurysms'
and ruptures of the aorta. Whether the hypertension
has a causative role in cystic medial necrosis or only
functions to propagate a tear is not fully understood.
Both of the patients in this report had undiag
nosed thyroid diseases at autopsy. In the first patient
Hashimoto's thyroiditis involved the entire gland.
The second had had a partial thyroidectomy and the
remaining thyroid tissue showed chronic thyroiditis.
There was diffuse fibrosis and multiple germinal cen
ters, but no Hlirthle cell change was seen in this
patient and we were therefore reluctant to classify
this as a classical Hashimoto's thyroiditis. The ana-
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tomic evidence suggests that both of these patients
could have had episodes of hypothyroidism which
were not detected, so-called preclinical myxedema.
The effect of total lhyroidectomy without thy
roid hormone replacement in hypertensive patients
has been documented by Kountz and Hempelmann.'
Two patients died of dissecting aneurysm within six
months. A third patient was treated with desiccated
thyroid for two years. She slopped taking her replace
ment hormone and ten months later died of dis
secting aneurysm. All three patients had cystic medial
necrosis. The findings suggest that hypothyroidism is
a severe risk factor in the development of dissecting
aortic aneurysm in hypertensive patients.
More recently an association of Hashimoto's
thyroiditis and dissecting aneurysm was reported.'
This case involved a patient who was also hyperten
sive and clinically hypothyroid. Thyroid auto-anti
bodies were present. Medial degeneration was not
documented. but severe atherosclerosis was present.
An association of hypothyroidism and abdominal
aneurysm has also been shown by Niarchos and
Finn. 3 They suggest that preclinical myxedema pa
tients might be picked up with a more sensitive
screening test. such as with antithyroid antibodies or
serum thyroid stimulating hormone (TSH) levels. In
addition. we suggest that patients with aortic
aneurysm might be screened more carefully for evi
dence of preclinical myxedema. In such patients. fur
ther weakening of the muscle wall might possibly be
prevented.
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ffush1ng or dryness of the skin may occur at higher dosage levels, rarely
at the usual dosage

each tablel.
capsule or 5 ml
(tsp J of elixir
(23 % alcohol)
( v.. gr) 16 2 mg
Phenobarb11a1
(warning may be hab11 lorm1ng)
O. 1037 mg
Hyoscyam1ne sulfate
O O194 mg
Atropine sulfate
Hyosc1ne hydrobromide
0.0065 mg

Indications: Based on a review of t111s drug by lhe NAS/NRC

each
Donnalal
No 2 Tablet
(Y2 gr) 32 4 mg
O 1037mg
0.0194 mg
0 0065 mg

A·H·ROBINS
A. H Robins Company, Richmond, Virginia 23220

and/or other information, FDA has classified the following indica
tions as possibly effective: adjunctive therapy in the treatment of
peptic ulcer: the treatment of the irritable bowel syndrome (irritable
colon. spastic colon. mucous colitis) and acute enterocolltis.
Final classif1cat1on of the less-than-effective indications requires
further invest1gat1on.

Briel summary. Contra1nd1cated 1n patients with glaucoma. renal or

hepatic disease, obstructive uropathy (for example, bladder neck
obstruction due to prostatic hypertrophy) or a hypersensitivity to any of
the 1ngred1ents. Blurred vision, dry mouth, difficult urination, and
flushing or dryness of the skin may occur at higher dosage levels, rarely
at the usual dosage

